| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.96.2.404 |
| P8608 | Fatcat ID | release_knlyg6hzvfaddiefmkxnpeo3ji |
| P698 | PubMed publication ID | 9244203 |
| P2093 | author name string | Gupta S | |
| Camm AJ | |||
| Kaski JC | |||
| Carrington D | |||
| Mendall MA | |||
| Leatham EW | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| myocardial infarction | Q12152 | ||
| antibody | Q79460 | ||
| azithromycin | Q165399 | ||
| Chlamydia pneumoniae | Q62869737 | ||
| P304 | page(s) | 404-407 | |
| P577 | publication date | 1997-07-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction | |
| P478 | volume | 96 |
| Q37879971 | A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide |
| Q37098266 | A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases |
| Q37875154 | A preliminary evaluation of a new enzyme immunoassay to detect Chlamydia pneumoniae-specific antibodies |
| Q35582538 | AIP1 prevents graft arteriosclerosis by inhibiting interferon-γ-dependent smooth muscle cell proliferation and intimal expansion |
| Q73718875 | Acute myocardial infarction and Helicobacter pylori seropositivity |
| Q43995973 | Acute respiratory-tract infections and risk of first-time acute myocardial infarction |
| Q35917262 | Advances in the management of Chlamydia pneumoniae infections |
| Q43429541 | Alternative hypothesis for efficacy of macrolides in acute coronary syndromes |
| Q35937166 | An Elevated Value of C-Reactive Protein is the Only Predictive Factor of Restenosis after Percutaneous Coronary Intervention |
| Q37875140 | Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events |
| Q35587190 | Antibiotic treatment of atherosclerosis |
| Q37873319 | Antibiotic use and risk of ischemic stroke in the elderly |
| Q37863427 | Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction |
| Q33588514 | Antibiotics for myocardial infarction? A possible role of infection in atherogenesis and acute coronary syndromes |
| Q24201388 | Antibiotics for secondary prevention of coronary heart disease |
| Q57389403 | Antibiotics for secondary prevention of coronary heart disease |
| Q37869381 | Antibiotics in primary prevention of myocardial infarction among elderly patients with hypertension |
| Q33935098 | Antibiotics in the prevention and treatment of coronary heart disease |
| Q37874993 | Antibodies to Chlamydia pneumoniae and clinical course in patients with unstable angina pectoris |
| Q37866484 | Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial |
| Q33726287 | Antimicrobial therapy for Chlamydia pneumoniae: its potential role in atherosclerosis and asthma |
| Q37880719 | Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection |
| Q34397021 | Assessment of subclinical atherosclerosis and cardiovascular risk. |
| Q34420129 | Association of HLA-DRB3*0202 and serum IgG antibodies to Chlamydia pneumoniae with essential hypertension in a highly homogeneous population from Majorca (Balearic Islands, Spain). |
| Q73250259 | Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study |
| Q33842403 | Atherogenesis and its relationship to coronary risk factors |
| Q37868568 | Atherogenic effects of chlamydia pneumoniae: refuting the innocent bystander hypothesis |
| Q39365197 | Atherosclerosis Induced by Chlamydophila pneumoniae: A Controversial Theory |
| Q52533070 | Atherosclerosis and acute coronary events. |
| Q35088632 | Atherosclerosis as a paradigmatic disease of the elderly: role of the immune system |
| Q37882083 | Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis |
| Q33843534 | Atherosclerosis, inflammation, and infection |
| Q33972834 | Atherosclerosis: an infectious disease? |
| Q37883441 | Atypical respiratory pathogens |
| Q37860076 | Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis |
| Q33935003 | Background and current knowledge of Chlamydia pneumoniae and atherosclerosis |
| Q27302171 | Biophysical regulation of Chlamydia pneumoniae-infected monocyte recruitment to atherosclerotic foci |
| Q33147741 | C-reactive protein as a predictor of improvement and readmission in heart failure |
| Q37870054 | C-reactive protein, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus and risk for myocardial infarction |
| Q37877470 | Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? |
| Q37882254 | Can we treat coronary artery disease with antibiotics? |
| Q38307119 | Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials. |
| Q33984369 | Cell wall-deficient bacteria as a cause of infections: a review of the clinical significance |
| Q43801101 | Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes |
| Q34005479 | Characterization of a streptococcal endopeptidase with homology to human endothelin-converting enzyme |
| Q37877285 | Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae |
| Q37875266 | Chlamydia Species and Mycoplasma pneumoniae |
| Q37870489 | Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in dialysis patients, renal transplant recipients and healthy controls |
| Q37346172 | Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis |
| Q51726841 | Chlamydia pneumoniae and Cardiovascular Disease. |
| Q33732232 | Chlamydia pneumoniae and anti-infective therapy: their role in the pathogenesis and treatment of coronary artery disease |
| Q73311061 | Chlamydia pneumoniae and atherosclerosis |
| Q37868049 | Chlamydia pneumoniae and atherosclerosis following carotid endarterectomy. |
| Q33534714 | Chlamydia pneumoniae and atherosclerosis. |
| Q33905858 | Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies |
| Q36180789 | Chlamydia pneumoniae and atherosclerosis: from Koch postulates to clinical trials |
| Q35758705 | Chlamydia pneumoniae and atherosclerosis: no way-out or long way? What about renal failure patients? |
| Q62279926 | Chlamydia pneumoniae and atherosclerotic cardiovascular disease |
| Q77729398 | Chlamydia pneumoniae and cardiovascular disease |
| Q33659387 | Chlamydia pneumoniae and coronary heart disease |
| Q37880994 | Chlamydia pneumoniae and occlusive vascular disease: identification and characterization |
| Q37880177 | Chlamydia pneumoniae and vascular disease |
| Q37878044 | Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in a sample population from Italy. |
| Q37869682 | Chlamydia pneumoniae antibodies and endothelial function as assessed by flow-mediated dilation in patients with chest pain with and without ischemic heart disease |
| Q35370873 | Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile |
| Q37873779 | Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). |
| Q33588103 | Chlamydia pneumoniae in arteries: the facts, their interpretation, and future studies |
| Q37228857 | Chlamydia pneumoniae in atheroma: consideration of criteria for causality |
| Q33890410 | Chlamydia pneumoniae in atherosclerosis |
| Q37879489 | Chlamydia pneumoniae in vascular tissue |
| Q37878378 | Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). |
| Q37862759 | Chlamydia pneumoniae infections augment atherosclerotic lesion formation: a role for serum amyloid P. |
| Q37872225 | Chlamydia pneumoniae seropositivity and the risk of nonarteritic ischemic optic neuropathy |
| Q33762172 | Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease |
| Q37875263 | Chlamydia pneumoniae, the Heart, and Coronary Artery Disease: Is There a Cause and Effect Relationship? |
| Q54063686 | Chlamydia pneumoniaeand atherosclerosis |
| Q37869989 | Chlamydial LPS antibodies, intima-media thickness and ischemic events in patients with established atherosclerosis |
| Q33842925 | Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages |
| Q37861545 | Chlamydial heat-shock protein 60 : A marker for chronic infection with Chlamydia Pneumoniae in atherosclerosis: Investigation of atherosclerotic coronary arteries by immunocytochemistry |
| Q37861559 | Chlamydophila pneumonia: Specific mRNA in aorta ascendens in patients undergoing coronary artery by-pass grafting |
| Q37870867 | Chronic Chlamydia pneumoniae infection in patients with coronary disease. Relation with increased fibrinogen values |
| Q33843633 | Chronic infection and coronary artery disease |
| Q79299394 | Chronic infection and coronary artery disease |
| Q33596962 | Chronic infection in the aetiology of atherosclerosis--focus on Chlamydia pneumoniae |
| Q37882065 | Chronic infection in the etiology of atherosclerosis--the case for Chlamydia pneumoniae |
| Q35371043 | Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease |
| Q34514051 | Chronic infections and atherosclerosis/thrombosis |
| Q73785566 | Chronic infections and coronary heart disease |
| Q51027473 | Cigarette smoking and inflammatory indices in coronary artery disease. |
| Q37877457 | Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease |
| Q33646625 | Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease |
| Q37864193 | Clearance of Chlamydia pneumoniae infection in H-2 class I human leucocyte antigen-A2.1 monochain transgenic mice |
| Q38211000 | Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. |
| Q33935109 | Collaborative multidisciplinary workshop report: clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease |
| Q37870081 | Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina |
| Q38537141 | Convergence in urban-rural prevalence of hypertension in India |
| Q43429573 | Coronary heart disease as inflammatory disease of the vascular bed? Etiology, sequela or misconception? |
| Q37877554 | Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies |
| Q43429360 | Current knowledge of Chlamydia pneumoniae and atherosclerosis |
| Q37880714 | Cytomegalovirus and herpes simplex virus in pathogenesis and progression of native arteriosclerosis and recurrent stenosis after intervention |
| Q37873684 | Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions |
| Q39709384 | Dental caries, periodontal disease, and cardiac arrhythmias in community-dwelling older persons aged 80 and older: is there a link? |
| Q37868027 | Dental infections and serum inflammatory markers in patients with and without severe heart disease. |
| Q34946766 | Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae |
| Q33781183 | Diagnosis and management of patients with unstable angina |
| Q33979917 | Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice |
| Q35140098 | Effect of clarithromycin on inflammatory markers in patients with atherosclerosis |
| Q33752851 | Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial |
| Q37875878 | Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction |
| Q37872800 | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model |
| Q37869839 | Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial |
| Q58808276 | Effects of Periodontal Therapy on Systemic Markers of Inflammation in Patients With Metabolic Syndrome: A Controlled Clinical Trial |
| Q33807200 | Effects of serine/threonine protein phosphatases on ion channels in excitable membranes |
| Q33987842 | Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. |
| Q33762166 | Emerging role of antibiotics in atherosclerosis |
| Q37881317 | Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease |
| Q61716910 | Etiology and response to drug treatment in heart failure |
| Q37880581 | Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction |
| Q34562273 | Evidence for infectious agents in cardiovascular disease and atherosclerosis |
| Q53564856 | Evolution of the management of acute myocardial infarction: a 20th century saga. |
| Q34877711 | Exacerbation of chronic inflammatory diseases by infectious agents: Fact or fiction? |
| Q30835828 | Fungal rDNA signatures in coronary atherosclerotic plaques |
| Q43427569 | Genitourinary chlamydial infection: a reappraisal and hypothesis |
| Q31032708 | Genomic approach for analysis of surface proteins in Chlamydia pneumoniae |
| Q35592372 | Helicobacter pylori and coronary heart disease: which directions for future studies? |
| Q40116049 | Helicobacter pylori infection and atherosclerosis: is there a causal relationship? |
| Q33821315 | Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease |
| Q34973446 | High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment |
| Q33286200 | Higher incidence of persistent chronic infection of Chlamydia pneumoniae among coronary artery disease patients in India is a cause of concern |
| Q33671907 | Histopathology of plaque rupture |
| Q37875208 | Identificaiton of chlamydia penumoniae DNA in caroitd plaques |
| Q34125106 | Identification of Chlamydia pneumoniae-derived mouse CD8 epitopes |
| Q58230333 | Immune system activation follows inflammation in unstable angina: pathogenetic implications |
| Q37878292 | Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. |
| Q37834775 | In vitro activity of a partially purified and characterized bark extract of Castanea sativa Mill. (ENC®) against Chlamydia spp. |
| Q37878178 | In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations |
| Q37880155 | In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. |
| Q37875577 | In vivo uptake of azithromycin in human coronary plaques |
| Q30891408 | Increase of arterial thrombosis parameters in chronic Helicobacter pylori infection in mice. |
| Q35586809 | Increased incidence of cytomegalovirus but not Chlamydia pneumoniae in atherosclerotic lesions of arteries of lower extremities from patients with diabetes mellitus undergoing amputation |
| Q31915357 | Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: a potential contributor to cardiovascular risk |
| Q37879391 | Infection and atherosclerosis--focus on cytomegalovirus and Chlamydia pneumoniae |
| Q33921219 | Infections and atherosclerosis |
| Q37092667 | Infectious causes of chronic inflammatory diseases and cancer |
| Q41701682 | Infectious diseases. More surprises |
| Q37874516 | Inflammation and infection in stable coronary disease and acute coronary syndrome |
| Q34316462 | Inflammation, infection and antimicrobial therapy in coronary heart disease--where do we currently stand? |
| Q33871329 | Inflammation, infection and atherosclerosis: do antibacterials have a role in the therapy of coronary artery disease? |
| Q35165193 | Inflammation, infection, and atherosclerosis |
| Q33935103 | Inflammation, infection, or both in atherosclerosis: the ROXIS trial in perspective |
| Q35201247 | Inflammatory and thrombotic mechanisms in coronary atherosclerosis |
| Q37875398 | Inflammatory cells, apoptosis and Chlamydia pneumoniae infection in atherosclerosis. |
| Q37871076 | Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study |
| Q42756397 | Inflammatory responses and coronary heart disease |
| Q37871579 | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model |
| Q37866065 | Influence of doxycycline on clinical and angiographic outcome following percutaneous coronary intervention |
| Q37881093 | Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease |
| Q30327329 | Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? |
| Q43426743 | Is atherosclerosis an infectious disease |
| Q33603398 | Is cardiovascular disease preventable by vaccination? |
| Q37879915 | Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis? |
| Q34237370 | Is the observed association between periodontitis and atherosclerosis causal? |
| Q73136940 | Is there an association between Helicobacter pylori infection and coronary heart disease? |
| Q37880514 | Is there an infective aetiology to atherosclerosis? |
| Q24802081 | Lack of association between Chlamydia Pneumoniae serology and endothelial dysfunction of coronary arteries |
| Q37093492 | Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline |
| Q37878909 | Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease |
| Q37877681 | Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis. |
| Q33767275 | Local immune responses to Chlamydia pneumoniae in the lungs of BALB/c mice during primary infection and reinfection |
| Q33772270 | Macrolide antibiotics and the risk of cardiac arrhythmias |
| Q36309930 | Macrolides in cystic fibrosis |
| Q33723966 | Management of unstable angina based on considerations of aetiology |
| Q33853043 | Markers of inflammation as predictors in cardiovascular disease |
| Q35583908 | Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques |
| Q50889858 | Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity. |
| Q34204611 | Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. |
| Q34286610 | Microbes, inflammation and atherosclerosis: will old pathology lessons guide new therapies? |
| Q34065709 | Microorganisms in the aetiology of atherosclerosis. |
| Q54286866 | Molecular study of human herpesvirus 6 and 8 involvement in coronary atherosclerosis and coronary instability. |
| Q36772861 | Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update |
| Q37869059 | Neopterin levels in patients with coronary artery disease are independent of Chlamydia pneumoniae seropositivity |
| Q56883926 | New and emerging infectious diseases |
| Q34382875 | New perspectives on macrolide antibiotics |
| Q34107356 | Novel risk factors for stroke: homocysteine, inflammation, and infection |
| Q37876321 | Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction |
| Q33723960 | Pathogenic mechanisms in unstable angina |
| Q37835617 | Peptide 19 of Porphyromonas gingivalis Heat Shock Protein Is a Potent Inducer of Low-Density Lipoprotein Oxidation |
| Q37880723 | Persistence of Chlamydia pneumoniae in human arteriosclerotic plaque substance. Evidence and consequences |
| Q36181163 | Persistent infection and vascular disease: a systematic review |
| Q33671913 | Plaque disruption and thrombosis. Potential role of inflammation and infection |
| Q59710269 | Plasma levels of interleukin 2, 6, 10 and phenotypic characterization of circulating T lymphocytes in ischemic heart disease |
| Q33935030 | Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells |
| Q37775097 | Possibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosis |
| Q34465370 | Potential infectious etiologies of atherosclerosis: a multifactorial perspective |
| Q34097321 | Predicting plaque rupture: enhancing diagnosis and clinical decision-making in coronary artery disease |
| Q77714696 | Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention |
| Q37873036 | Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. |
| Q37876537 | Prior cytomegalovirus, Chlamydia pneumoniae or Helicobacter pylori infection and the risk of restenosis after percutaneous transluminal coronary angioplasty |
| Q37295072 | Pro-atherogenic lung and oral pathogens induce an inflammatory response in human and mouse mast cells |
| Q37876806 | Protective DNA immunization against Chlamydia pneumoniae |
| Q34248742 | Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial |
| Q43697974 | Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion |
| Q35143299 | Rational antibacterial vaccine design through genomic technologies |
| Q33843402 | Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention |
| Q33791941 | Recent advances. General medicine |
| Q37873120 | Relation of Chlamydia pneumoniae infection in Taiwan to angiographically demonstrated coronary artery disease and to the presence of acute myocardial infarction or unstable angina pectoris. |
| Q37878617 | Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study |
| Q37872836 | Relation of antibiotic use to risk of myocardial infarction in the general population |
| Q34698619 | Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease |
| Q46738236 | Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide |
| Q34874476 | Role of antibiotics for the prevention of cardiovascular disease |
| Q33942966 | Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis |
| Q43425170 | Secondary prevention antibiotic treatment trials. |
| Q33762181 | Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues |
| Q37876599 | Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis |
| Q37844983 | Shear Stress Enhances Chemokine Secretion from Chlamydia pneumoniae-infected Monocytes |
| Q34160606 | Should antibiotics now be part of routine treatment of coronary heart disease? |
| Q36091141 | Sophisticated tests for susceptibility to atherosclerosis: an added value for heart hospitals |
| Q88248631 | Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides |
| Q37568474 | Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice |
| Q37876315 | The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). |
| Q33714051 | The anti-inflammatory effects of macrolides |
| Q33888246 | The antimicrobial treatment of periodontal disease: changing the treatment paradigm |
| Q57740621 | The association of chronic cough with the risk of myocardial infarction: the Framingham Heart Study |
| Q34075142 | The association of infection and coronary artery disease: an update |
| Q37870997 | The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study |
| Q42933346 | The failure of antibiotics to prevent heart attacks |
| Q36482515 | The interaction of bacterial pathogens with platelets |
| Q37867657 | The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations |
| Q48287971 | The nitric oxide hypothesis of aging |
| Q33770472 | The possible role of infections in acute myocardial infarction |
| Q37879200 | The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery |
| Q43427761 | The role of Chlamydia in coronary heart disease-fact or fiction? |
| Q43428884 | The role of Chlamydia pneumoniae in the pathogenesis of atherosclerosis |
| Q37880009 | The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection |
| Q40409051 | The role of cytokines in unstable angina |
| Q35080677 | The role of infection in the pathogenesis of cardiovascular disease |
| Q33870602 | The role of plaque rupture and thrombosis in coronary artery disease |
| Q34447107 | The role of risk factors in the development of atherosclerosis |
| Q33923440 | The unfolding story of the chaperonins |
| Q34067823 | The use of serologic tests for the diagnosis of chlamydial infections |
| Q34293729 | Therapeutic implications of inflammation in atherosclerotic cardiovascular disease |
| Q73321594 | Thrombogenesis and fibrinolysis in acute coronary syndromes. Important facets of a prothrombotic or hypercoagulable state? |
| Q33671919 | Thrombosis and coagulation abnormalities in the acute coronary syndromes |
| Q37874002 | Treating cardiovascular disease with antimicrobial agents: a survey of knowledge, attitudes, and practices among physicians in the United States |
| Q37873906 | Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial |
| Q35632398 | Trends in hypertension epidemiology in India |
| Q35962028 | Use of macrolides and tetracyclines for chronic inflammatory diseases |
| Q73382390 | Vaccination against infections by Chlamydia pneumoniae |
| Q35692035 | Vaccination and atherosclerosis |
| Q34514026 | Vascular inflammation as a therapeutic target for prevention of cardiovascular disease |
| Q34011168 | Weighing the evidence for infection as a risk factor for coronary heart disease |
| Q78006813 | [Angiology update] |
| Q74043506 | [Current topics in vascular biology: an update for the 21st century] |
| Q73298197 | [Endothelial dysfunction in patients with acute coronary syndrome] |
| Q73656227 | [Infection and atherosclerosis] |
| Q74310027 | [Infections and arteriosclerosis: science or fiction?] |
| Q77653051 | [Inflammation and cardiac disease] |
| Q73353360 | [Prognostic value of the determination of C-reactive protein in unstable angina] |
| Q74436270 | [Role of infectious agents in the understanding of atherosclerosis] |
| Q54138041 | [Therapeutic options for improvement of myocardial perfusion in coronary atherosclerosis]. |
Search more.